Fig. 1
Development of acquired platinum resistance, TNFAIP2 expression, and outcomes. a WB analysis of TNFAIP2 in platinum-naïve 5637 and platinum-resistance 5637PR cells. b mRNA expression of TNFAIP2 in 5637 and 5637PR cells. c Immunofluorescence staining for TNFAIP2 in 5637 and 5637PR cells. Bar, 100 µm. *P < 0.05, from the Student’s t-test. Box plots show a significant difference in TNFAIP2 expression between low grade (n = 44) vs high grade (n = 112) (d), and <pT3 (n = 81) vs ≥pT3 (n = 75) patients (e). P values from the Mann–Whitney U-test. f Representative images of TNFAIP2 expression from pTa, low-grade (LG), and lymphovascular invasion (LVI)-negative superficial tumors and pT3, high-grade (HG), LVI-positive muscle-invasive tumors. Bar, 100 µm. Kaplan–Meier curves according to TNFAIP2 expression of the recurrence-free (g) and cancer-specific survival (h) of 156 patients with upper urinary tract urothelial cancer following surgery. P values from the log-rank test
